Cardiol Therapeutics is a clinical-stage biopharmaceutical company developing anti-inflammatory and anti-fibrotic therapies for heart diseases, with its lead candidate CardiolRx, a cannabidiol oral solution, in Phase II clinical trials for recurrent pericarditis and acute myocarditis. The company uses proprietary nanotechnology based on biodegradable polymers for targeted drug delivery to inflamed cardiac tissue, and is also developing CRD-38, a subcutaneous formulation candidate for heart failure treatment. Cardiol generates value through intellectual property including multiple patent families covering cannabidiol formulations and methods for treating cardiovascular conditions, partnerships with manufacturing and supply partners, and potential future licensing agreements and royalties from pharmaceutical partners in late-stage development and commercialization.